Abstract Details

Title MRI Activity in Secondary Progressive Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-016

Objective Assess the rate of secondary progressive multiple sclerosis (SPMS) patients who exhibit contrast-enhancing or new T2 lesions on magnetic resonance imaging (MRI) scans and identify possible influencing factors.

Background SPMS patients have lower MRI activity. It is important to identify patients with higher activity and determine the differences between SPMS patients with and without new or active MRI lesions.

Design/Methods SPMS patients with disease duration ≥ 10 years and EDSS score ≥ 4.0 that performed brain MRI with or without cervical and thoracic spinal cord MRI between the years 2015- 2019 were included in the study. We assessed the rate of contrast-enhancing or new T2 lesions in relation to disease modifying therapies (DMT) and demographic variables.

Results

255 SPMS patients were included. The patients mean age was 53.0 years with median EDSS of 6.0 and mean disease duration of 22 years. 61.1% were treated with DMT. 26.6% had MRI activity. Within the active MRI patients, 57.3% received DMT for a period of 4.5 years as compared to 62.5% of patients in the non-active MRI group treated for 6.0 years, P=0.0145. SPMS patients with active MRI were younger in approximately six years compared to the non-active MRI group 48.3±9.56 vs 54.8±10.66 years of age, P <0.01. No differences related to gender, disease duration or EDSS were found.

Conclusions

26.6% of SPMS patients have MRI activity. These patients are younger and receive DMT for a shorter period of time.

Authors/Disclosures
Daniella Zohar PRESENTER	No disclosure on file
Anat Achiron, MD, PhD, F�鶹��ýӳ�� (Sheba Medical Center, Tel-Hashomer)	Dr. Achiron has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��